Lori Anne Kunkel - May 19, 2025 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Director
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Lori Ann Kunkel
Stock symbol
NRIX
Transactions as of
May 19, 2025
Transactions value $
$0
Form type
4
Date filed
5/19/2025, 05:33 PM
Previous filing
Mar 4, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kunkel Lori Anne Director C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO /s/ Daniel Burbach, as Attorney-in-Fact for Lori Ann Kunkel 2025-05-19 0001536368

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Director Stock Option (right to buy) Award $0 +25K $0.00 25K May 19, 2025 Common Stock 25K $9.51 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.